Solaprubart (Synonyms: STAR-0310) |
Catalog No.GC79277
One-Click Copy Product Info
|
Solaprubart (STAR-0310) is a fully human IgG1 subtype monoclonal antibody targeting OX40 (CD134/TNFRSF4), with a K d of 7.2 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 3057433-10-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vitro, Solaprubart (0.1-1000 nM) potently inhibits the release of IFNγ, TNF-α, IL-5 and IL-13 from pre-activated human T cells, with EC50 values of 11.8, 4.2, 16.4 and 5.3 nM, respectively[1]. Solaprubart (0-100 nM) significantly reduces ADCC activity against activated human T cells and regulatory human T cells, with EC50 values of 0.1 nM and 2.31 nM, respectively[1].
References:
[1]. Biris N, et al. Development and characterization of STAR-0310: a novel OX40 antagonistic monoclonal antibody. Cells. 2024;13(7).
[2]. Biris N, et al. A Dual-Action Mechanism to Prevent OX40 Signaling: The Structural Basis for the Differentiated Antagonist STAR-0310. bioRxiv. 2025 Sep 19:2025-09.
| Cas No. | 3057433-10-7 | SDF | |
| Synonyms | STAR-0310 | ||
| Formula | M.Wt | 145.35 | |
| Solubility | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.8799 mL | 34.3997 mL | 68.7994 mL |
| 5 mM | 1.376 mL | 6.8799 mL | 13.7599 mL |
| 10 mM | 688 μL | 3.44 mL | 6.8799 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)